| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/27/2007 | US20070225241 Tfiis and gdown1 as targets for cancer therapy |
| 09/27/2007 | US20070225228 Blockade of gamma-secretase activity to promote myelination by oligodendrocytes |
| 09/27/2007 | US20070225214 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 09/27/2007 | US20070225213 Nucleic acid carriers for delivery of therapeutic agents |
| 09/27/2007 | US20070224681 Collapsin response mediator protein-1 (CRMP-1) transcriptional regulatory nucleic acid sequences |
| 09/27/2007 | US20070224679 Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA |
| 09/27/2007 | US20070224257 Brucellosis dna vaccine |
| 09/27/2007 | US20070224219 dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants |
| 09/27/2007 | US20070224210 Immunostimulatory nucleic acids |
| 09/27/2007 | US20070224196 Immunogenicity-reduced anti-cr1 antibody and compositions and methods of treatment based thereon |
| 09/27/2007 | US20070224195 Antitumor agents; enhanced by administration of cytoxic T lymphocyte (CTLA-4) blocker and/or cytosine-guanosine (CpG) oligodeoxynucleotide immunomodulators |
| 09/27/2007 | US20070224177 Cell populations which co-express CD49c and CD90 |
| 09/27/2007 | US20070224176 introducing an oligonucleotide into a donor cell, particularly a stem cell, and contacting the target cell with the donor cell under conditions permitting the donor cell to form a gap junction channel composed of connexin 43 with the target cell, thus donor cell delivers oligonucleotide to target cell |
| 09/27/2007 | US20070224171 Genetically engineered cells for therapeutic applications |
| 09/27/2007 | US20070224170 Adenovirus/Alphavirus Hybrid Vector for the Effective Administration and Expression of Therapeutic Genes in Tumour Cells |
| 09/27/2007 | US20070224169 Selectively switched gels for surgery, therapy and maintenance |
| 09/27/2007 | US20070224123 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines |
| 09/27/2007 | US20070224122 Method of in vitro diagnosis which discriminates between exposure of a subject to Mycobacterium tuberculosis and vaccination with Bacille Calmette Guerin strain of Mycobacterium bovis, method comprising testing for presence of CD4 T lymphocytes that respond to MTBN4 |
| 09/27/2007 | CA2647769A1 Control of intracellular target molecule by ip3 receptor-binding protein |
| 09/27/2007 | CA2645120A1 Treatment of cns conditions |
| 09/26/2007 | EP1837398A1 Drugs for diseases accompanying changes in total bile acid pool or lipid metabolism disorders and method of screening these drugs |
| 09/26/2007 | EP1837342A2 Sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 09/26/2007 | EP1837035A1 Therapeutic agent for chronic obstructive pulmonary disease (copd), cystic fibrosis or pulmonary hypertension |
| 09/26/2007 | EP1837034A1 Remedy for alzheimer´s disease |
| 09/26/2007 | EP1837031A1 Compositions and methods for treating diabetes |
| 09/26/2007 | EP1837017A2 Microparticles for delivery of nucleic acid |
| 09/26/2007 | EP1836300A1 Cancer-targeted viral vectors |
| 09/26/2007 | EP1653808A4 Neurogenin3 and production of pancreatic islet cells |
| 09/26/2007 | EP1409740B1 Asthma-associated gene |
| 09/26/2007 | EP1222255B1 Polypeptide fragments comprising c-terminal portion of helicobacter catalase |
| 09/26/2007 | EP1198239B1 METHODS EMPLOYING BACTERIAL ParD kis/ParD kid TOXIN-ANTITOXIN SYSTEM FOR KILLING EUKARYOTIC CELLS |
| 09/26/2007 | EP1153131B1 Compositions for gene therapy of diabetes |
| 09/26/2007 | EP1035865B1 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 09/26/2007 | EP1025212B1 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities |
| 09/26/2007 | EP0991663B1 Mycobacterium strain with modified erp gene and vaccine composition containing same |
| 09/26/2007 | CN101044247A Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 09/26/2007 | CN101041680A Nucleic acid molecule RTN4BSR6 and application for preparation of anti-cancer drugs |
| 09/26/2007 | CN101041679A Structure of siRNA for target survivin gene and antineoplastic usage |
| 09/26/2007 | CN101041079A Novel colloid synthetic vectors for gene therapy |
| 09/26/2007 | CN101041078A Biology agent for improving radiosensitization of tumor cells and the use thereof |
| 09/26/2007 | CN101040847A Nanometer medicine agent produced by hydrogenated castor oil and the technique of preparing the same |
| 09/26/2007 | CN100339394C 组织特异性表达 Tissue-specific expression |
| 09/25/2007 | US7273932 Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use |
| 09/25/2007 | US7273928 Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin |
| 09/25/2007 | US7273923 Plant protein for use as tool in cintrolling gene expression plants |
| 09/25/2007 | US7273855 Single stranded oligonucleotides of DNA or RNA, particularly RNA transcribed from portions of wild type prohibitin 3'UTR, into tumors leads to arrested cell proliferation. Significant reduction in the size of primary tumors has been observed |
| 09/25/2007 | US7273854 Recombinant adenovirus, adeno-associated virus or herpes virus (especially a replication defective virus) containing a nucleic acid of a specific sequence encoding an antisense RNA that inhibits expression of p53. |
| 09/25/2007 | US7273848 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 09/25/2007 | US7273843 Methods of treating allergy by administering interleukin-17 receptor |
| 09/25/2007 | US7273752 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, |
| 09/25/2007 | US7273751 Comprises nucleotide sequences associated with expression vector coding endothelial growth factor for use in diagnosis and treatment of tumor angiogenesis, inflammation, diabetic retinopathy, arthritis and psoriasis; wound healing agent |
| 09/25/2007 | US7273744 Heparanase-like polypeptides |
| 09/25/2007 | US7273725 Human and mammalian stem cell-derived neuron survival factors |
| 09/25/2007 | US7273698 Defects in periaxin associated with myelinopathies |
| 09/25/2007 | US7273612 Soluble inhibitors of vascular endothelial growth factor and use thereof |
| 09/25/2007 | US7273605 Containing a priming and boosting composition, each with a non-replicating viral vector, with at least one of them being derived from a fowlpox virus; malaria, tuberculosis |
| 09/25/2007 | CA2294649C Bovine adenovirus type 3 genome |
| 09/25/2007 | CA2204160C Treatment of urogenital cancer with boron neutron capture therapy |
| 09/25/2007 | CA2192442C Complementary adenoviral vector systems and cell lines |
| 09/20/2007 | WO2007106476A2 Compositions and methods for enhancing the immunogenicity of antigens |
| 09/20/2007 | WO2007106404A2 Vaccine for viruses that cause persistent or latent infections |
| 09/20/2007 | WO2007106351A2 Porous silicon materials and devices |
| 09/20/2007 | WO2007106072A2 Isolated complexes of endotoxin and modified md-2 |
| 09/20/2007 | WO2007105744A1 Purkinje cell-tropic viral vector |
| 09/20/2007 | WO2007105218A2 Composition and method for brain tumor therapy |
| 09/20/2007 | WO2007104581A1 Use of recombinant modified vaccinia virus ankara (mva) for the treatment of type 1 hypersensitivity in a living animal including humans |
| 09/20/2007 | WO2007071994A3 Viral vectors |
| 09/20/2007 | WO2007058527A3 Inducible expression systems |
| 09/20/2007 | WO2005120152A3 Cationic lipids and methods of use |
| 09/20/2007 | US20070220620 TAT-046 and methods of assessing and treating cancer |
| 09/20/2007 | US20070219155 Treating trinucleotide repeat conditions |
| 09/20/2007 | US20070219154 Methods for preventing and/or treating a cell proliferative disorder |
| 09/20/2007 | US20070219153 Immunostimulatory activity of immune modulatory oligonucleotides (IMOtm) containing different lengths of palindromic segments |
| 09/20/2007 | US20070219152 Inhibition of Syk kinase expression |
| 09/20/2007 | US20070219151 Methods and compositions for inhibiting the function of polynucleotide sequences |
| 09/20/2007 | US20070219150 Nerve Cell Differentiation Inducer |
| 09/20/2007 | US20070219149 Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Immunity |
| 09/20/2007 | US20070219122 Modified triple-helix forming oligonucleotides for targeted mutagenesis |
| 09/20/2007 | US20070219118 Therapeutic methods for nucleic acid delivery vehicles |
| 09/20/2007 | US20070218511 Methods for the diagnosis and treatment of lung cancer |
| 09/20/2007 | US20070218470 Method for selective inactivation of viral replication |
| 09/20/2007 | US20070218469 Novel mutations in hexosaminidase A |
| 09/20/2007 | US20070218122 siRNA silencing of influenza virus gene expression |
| 09/20/2007 | US20070218077 Lipid-Mediated Polynucleotide Administration to Deliver a Biologically Active Peptide and to Induce a Cellular Immune Response |
| 09/20/2007 | US20070218068 Human Autism Predisposition Gene Encoding a Transcription Factor and Uses Thereof |
| 09/20/2007 | US20070218067 useful for monitoring the (de)activation status if the patient is treated with thrombocyte aggregation inhibitors |
| 09/20/2007 | US20070218061 Use of ephrinb2 directed agents for the treatment or prevention of viral infections |
| 09/20/2007 | US20070218038 Stabilized, sterilized collagen scaffolds with active adjuncts attached |
| 09/20/2007 | US20070218032 B7-h4 expression on tumor vasculature |
| 09/20/2007 | US20070218003 Truncated Dance, Dance Complex And Method Of Using These |
| 09/20/2007 | DE19882435B4 Verfahren zur Hemmung von Krebszellwachstum mit einem pRb2/p130 exprimierenden Vektor Methods of inhibiting cancer cell growth with a pRb2 / p130 expressing vector |
| 09/20/2007 | DE102006054192A1 Method for loading nucleic acid active substances within amphoteric liposomes, comprises: mixing lipid mixture solution and aqueous solution of nucleic acid active substances; and sterile filtrating the liposomes containing the substances |
| 09/20/2007 | CA2645507A1 Vaccine for viruses that cause persistent or latent infections |
| 09/19/2007 | EP1835031A1 Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
| 09/19/2007 | EP1835027A1 Novel cancer antigen peptide and the use thereof |
| 09/19/2007 | EP1834960A2 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 09/19/2007 | EP1833986A1 Determinants of sensitivity to chemotherapeutic agents |
| 09/19/2007 | EP1833975A2 Regulated expression of transgenes in the central nervous system of mammals |
| 09/19/2007 | EP1833844A1 Signal peptides, nucleic acid molecules and methods of treatment |
| 09/19/2007 | EP1833838A2 Cationic liposomes comprising a charge neutral compound and a cationic phospholipid |